Aura Biosciences Inc AI Stock Analysis
Want to see AURA full AI Analyst Report?
Aura Biosciences Inc (AURA) AI Stock Analysis
Aura Biosciences Inc
(NASDAQ:AURA)
The score is primarily held back by pre-revenue financials with widening losses and substantial ongoing cash burn, despite a low-debt balance sheet that supports near-term stability. Technicals are mixed/neutral without strong momentum, valuation signals are weak due to negative earnings and no dividend, and corporate events are modestly supportive due to Phase 3 progress but tempered by restructuring and rising expenses.
Aura Biosciences Inc (AURA) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $739.97M
- Dividend Yield
- ―
- Average Volume (3M)
- 900.47K
- Price to Earnings (P/E)
- -4.3
- Beta (1Y)
- 1.52
- Revenue Growth
- ―
- EPS Growth
- 13.33%
- Country
- US
- Employees
- 113
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Aura Biosciences Inc Business Overview & Revenue Model
Company Description
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform...
Aura Biosciences Inc Financial Statement Overview
Summary
Financials reflect a development-stage biotech profile: no revenue and widening losses alongside heavy cash burn (negative operating/free cash flow in TTM). The main offset is a comparatively strong, low-leverage balance sheet with meaningful equity, which reduces near-term solvency risk but does not eliminate longer-term funding risk if burn persists.
Income Statement
18Very NegativeBalance Sheet
66PositiveCash Flow
24Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | -1.29M | 0 | 0 |
| EBITDA | -141.29M | -104.95M | -85.58M | -74.98M | -57.59M | -34.41M |
| Net Income | -136.95M | -106.19M | -86.92M | -76.41M | -58.76M | -35.25M |
Balance Sheet | ||||||
| Total Assets | 321.62M | 169.43M | 182.50M | 255.07M | 223.94M | 160.03M |
| Cash, Cash Equivalents and Short-Term Investments | 297.23M | 144.24M | 151.09M | 226.15M | 188.81M | 149.06M |
| Total Debt | 16.17M | 17.38M | 18.77M | 19.56M | 20.86M | 975.00K |
| Total Liabilities | 34.19M | 32.52M | 30.53M | 29.23M | 28.35M | 7.71M |
| Stockholders Equity | 287.43M | 136.91M | 151.97M | 225.85M | 195.58M | 152.31M |
Cash Flow | ||||||
| Free Cash Flow | -109.68M | -85.19M | -81.06M | -64.56M | -55.70M | -34.53M |
| Operating Cash Flow | -109.30M | -84.74M | -79.81M | -63.85M | -54.60M | -32.41M |
| Investing Cash Flow | -141.20M | 35.59M | 68.82M | -113.96M | -67.87M | -2.13M |
| Financing Cash Flow | 245.03M | 77.16M | 1.59M | 97.29M | 95.63M | 166.26M |
Aura Biosciences Inc Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AURA, the sentiment is Positive. The current price of 7.11 is above the 20-day moving average (MA) of 6.62, above the 50-day MA of 6.54, and above the 200-day MA of 6.79, indicating a bullish trend. The MACD of 0.22 indicates Negative momentum. The RSI at 57.29 is Neutral, neither overbought nor oversold. The STOCH value of 66.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AURA.
Aura Biosciences Inc Risk Analysis
Aura Biosciences Inc disclosed 69 risk factors in its most recent earnings report. Aura Biosciences Inc reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
2 New RisksAura Biosciences Inc Peers Comparison
Overall Rating
IRD53Neutral
AURA52Neutral
FDMT45Neutral
EYPT38.2Underperform
OCS38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 53Neutral | $384.68M | -2.60 | 9999.00% | ― | -45.92% | 10.87% | |
| 52Neutral | $739.97M | -4.26 | -64.69% | ― | ― | 13.33% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 45Neutral | $675.64M | -4.38 | -47.06% | ― | 79952.50% | 29.07% | |
| 38Underperform | $34.82M | -0.08 | -168.83% | ― | -93.91% | -32.55% | |
| 38Underperform | $471.63M | -4.64 | -39.51% | ― | ― | 31.72% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AURA | Aura Biosciences Inc | 7.11 | 1.61 | 29.27% | |
| EYPT | Eyepoint Pharma | 0.31 | -12.83 | -97.67% | |
| IRD | Opus Genetics, Inc. | 3.98 | 2.24 | 128.74% | |
| FDMT | 4D Molecular Therapeutics, Inc. | 12.23 | 1.28 | 11.69% | |
| OCS | Oculis Holding Ag | 7.64 | -11.51 | -60.10% | |
| SGP | SpyGlass Pharma | 32.88 | 6.48 | 24.55% |
Aura Biosciences Inc Corporate Events
Aura Biosciences Reports Third-Quarter Results and Clinical Progress
NegativeOn November 9, 2026, Aura reported third-quarter results for the period ended September 30 and updated its corporate presentation for investor and analyst meetings. Enrollment was complete in its Phase 3 CoMpass trial, with 108 participants having co...
Aura Biosciences Restructures, Refocuses on Ocular Oncology
NegativeAura Biosciences reported second-quarter 2026 results on August 11, 2026, highlighting full enrollment of its Phase 3 CoMpass trial in early choroidal melanoma, with 108 patients and topline data expected in the second half of 2027. The trial, conduc...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 10, 2026
